Raynaud's phenomenon: Pathophysiologic features and treatment with calcium-channel blockers

Craig R. Smith, Richard J. Rodeheffer

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Raynaud's phenomenon may be associated with severe pain, functional disability and digital infarction, particularly in patients with underlying vascular disease. The pathophysiologic features of Raynaud's phenomenon are complex although vasospasm contributes to the production of digital ischemia in most cases. Calcium-channel blockers have been shown to produce arteriolar vasodilation and an increase in peripheral blood flow. They have been used to treat patients with Raynaud's phenomenon in several prospective, randomized, double-blind, placebo-controlled trials. Low doses of verapamil were ineffective but both diltiazem and nifedipine produced subjective improvement in 60 to 90% of cases. Objective measures of digital blood flow were not improved. Patients without underlying vascular disease responded more readily to therapy than patients with scleroderma. Adverse effects were uncommon and seldom necessitated discontinuation of therapy. These data suggest that nifedipine and diltiazem provide effective short-term improvement in symptoms for most patients with Raynaud's phenomenon.

Original languageEnglish (US)
JournalThe American Journal of Cardiology
Volume55
Issue number3
DOIs
StatePublished - Jan 25 1985
Externally publishedYes

Fingerprint

Raynaud Disease
Calcium Channel Blockers
Diltiazem
Nifedipine
Vascular Diseases
Therapeutics
Verapamil
Vasodilation
Infarction
Ischemia
Placebos
Pain

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Raynaud's phenomenon : Pathophysiologic features and treatment with calcium-channel blockers. / Smith, Craig R.; Rodeheffer, Richard J.

In: The American Journal of Cardiology, Vol. 55, No. 3, 25.01.1985.

Research output: Contribution to journalArticle

@article{027734c58a7746768062d69f82a2f6c2,
title = "Raynaud's phenomenon: Pathophysiologic features and treatment with calcium-channel blockers",
abstract = "Raynaud's phenomenon may be associated with severe pain, functional disability and digital infarction, particularly in patients with underlying vascular disease. The pathophysiologic features of Raynaud's phenomenon are complex although vasospasm contributes to the production of digital ischemia in most cases. Calcium-channel blockers have been shown to produce arteriolar vasodilation and an increase in peripheral blood flow. They have been used to treat patients with Raynaud's phenomenon in several prospective, randomized, double-blind, placebo-controlled trials. Low doses of verapamil were ineffective but both diltiazem and nifedipine produced subjective improvement in 60 to 90{\%} of cases. Objective measures of digital blood flow were not improved. Patients without underlying vascular disease responded more readily to therapy than patients with scleroderma. Adverse effects were uncommon and seldom necessitated discontinuation of therapy. These data suggest that nifedipine and diltiazem provide effective short-term improvement in symptoms for most patients with Raynaud's phenomenon.",
author = "Smith, {Craig R.} and Rodeheffer, {Richard J.}",
year = "1985",
month = "1",
day = "25",
doi = "10.1016/0002-9149(85)90625-3",
language = "English (US)",
volume = "55",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Raynaud's phenomenon

T2 - Pathophysiologic features and treatment with calcium-channel blockers

AU - Smith, Craig R.

AU - Rodeheffer, Richard J.

PY - 1985/1/25

Y1 - 1985/1/25

N2 - Raynaud's phenomenon may be associated with severe pain, functional disability and digital infarction, particularly in patients with underlying vascular disease. The pathophysiologic features of Raynaud's phenomenon are complex although vasospasm contributes to the production of digital ischemia in most cases. Calcium-channel blockers have been shown to produce arteriolar vasodilation and an increase in peripheral blood flow. They have been used to treat patients with Raynaud's phenomenon in several prospective, randomized, double-blind, placebo-controlled trials. Low doses of verapamil were ineffective but both diltiazem and nifedipine produced subjective improvement in 60 to 90% of cases. Objective measures of digital blood flow were not improved. Patients without underlying vascular disease responded more readily to therapy than patients with scleroderma. Adverse effects were uncommon and seldom necessitated discontinuation of therapy. These data suggest that nifedipine and diltiazem provide effective short-term improvement in symptoms for most patients with Raynaud's phenomenon.

AB - Raynaud's phenomenon may be associated with severe pain, functional disability and digital infarction, particularly in patients with underlying vascular disease. The pathophysiologic features of Raynaud's phenomenon are complex although vasospasm contributes to the production of digital ischemia in most cases. Calcium-channel blockers have been shown to produce arteriolar vasodilation and an increase in peripheral blood flow. They have been used to treat patients with Raynaud's phenomenon in several prospective, randomized, double-blind, placebo-controlled trials. Low doses of verapamil were ineffective but both diltiazem and nifedipine produced subjective improvement in 60 to 90% of cases. Objective measures of digital blood flow were not improved. Patients without underlying vascular disease responded more readily to therapy than patients with scleroderma. Adverse effects were uncommon and seldom necessitated discontinuation of therapy. These data suggest that nifedipine and diltiazem provide effective short-term improvement in symptoms for most patients with Raynaud's phenomenon.

UR - http://www.scopus.com/inward/record.url?scp=0021988264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021988264&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(85)90625-3

DO - 10.1016/0002-9149(85)90625-3

M3 - Article

C2 - 3881908

AN - SCOPUS:0021988264

VL - 55

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 3

ER -